Karen Coderre, PharmD, and Madhavi Manduru-Rao, PharmD, detail how CMS' increased weighting for Consumer Assessment of Health Care Providers and Systems surveys impacts Star ratings.
Karen Coderre, PharmD, is director, Pharmacy Clinical Management and Quality, and Madhavi Manduru-Rao, PharmD, is manager, Pharmacy Quality Programs, at BlueCross BlueShield of North Carolina.
Transcript
What change did CMS make to 2021 health plans, and how do Consumer Assessment of Health Care Providers and Systems (CAHPS) surveys affect various Medicare Star ratings?
Coderre: So, the changes that CMS made for experience in 2021 is they doubled the weight of the member experience rating for Medicare stars. Basically, it used to be double weighted last year score and now it is quadruple weighted. So, because of that, almost one-third of your overall Star rating is going to be impacted by your member experience and access to care, and that's measured by CAHPS surveys, which Madhavi be can talk about.
Manduru-Rao: It's always on the back of our mind to make sure that we always keep an eye on [member experience] either through an interaction with a phone call with a member or doing a comprehensive medication review. It's to make sure that that contact with the member is the best possible and that the member leaves feeling, "I got the answer I wanted," so when they come back and rate the drug plan or rate the health plan through these CAHPS surveys, hopefully, they will rate us with a higher number based on those experiences.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More